Institute of Clinical Medicine, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, 410005, P.R. China.
Department of Cardiac Thoracic Surgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China.
BMC Cancer. 2023 May 6;23(1):408. doi: 10.1186/s12885-023-10895-2.
More and more studies have demonstrated that potassium channel tetramerization domain-containing 5 (KCTD5) plays an important role in the development of cancer, but there is a lack of comprehensive research on the biological function of this protein in pan-cancer. This study systematically analyzed the expression landscape of KCTD5 in terms of its correlations with tumor prognosis, the immune microenvironment, programmed cell death, and drug sensitivity.
We investigated a number of databases, including TCGA, GEPIA2, HPA, TISIDB, PrognoScan, GSCA, CellMiner, and TIMER2.0. The study evaluated the expression of KCTD5 in human tumors, as well as its prognostic value and its association with genomic alterations, the immune microenvironment, tumor-associated fibroblasts, functional enrichment analysis, and anticancer drug sensitivity. Real-time quantitative PCR and flow cytometry analysis were performed to determine the biological functions of KCTD5 in lung adenocarcinoma cells.
The results indicated that KCTD5 is highly expressed in most cancers and that its expression is significantly correlated with tumor prognosis. Moreover, KCTD5 expression was related to the immune microenvironment, infiltration by cancer-associated fibroblasts, and the expression of immune-related genes. Functional enrichment analysis revealed that KCTD5 is associated with apoptosis, necroptosis, and other types of programmed cell death. In vitro experiments showed that knockdown of KCTD5 promoted apoptosis of A549 cells. Correlation analysis confirmed that KCTD5 was positively correlated with the expression of the anti-apoptotic genes Bcl-xL and Mcl-1. Additionally, KCTD5 was significantly associated with sensitivity to multiple antitumor drugs.
Our results suggest that KCTD5 is a potential molecular biomarker that can be used to predict patient prognosis, immunoreactions and drug sensitivity in pan-cancer. KCTD5 plays an important role in regulating programmed cell death, especially apoptosis.
越来越多的研究表明钾通道四聚化结构域包含 5 型(KCTD5)在癌症的发展中起着重要作用,但缺乏对这种蛋白质在泛癌中的生物学功能的全面研究。本研究系统地分析了 KCTD5 的表达谱,包括其与肿瘤预后、免疫微环境、程序性细胞死亡和药物敏感性的相关性。
我们研究了多个数据库,包括 TCGA、GEPIA2、HPA、TISIDB、PrognoScan、GSCA、CellMiner 和 TIMER2.0。研究评估了 KCTD5 在人类肿瘤中的表达,以及其预后价值及其与基因组改变、免疫微环境、肿瘤相关成纤维细胞、功能富集分析和抗癌药物敏感性的关系。实时定量 PCR 和流式细胞术分析用于确定 KCTD5 在肺腺癌细胞中的生物学功能。
结果表明,KCTD5 在大多数癌症中高表达,其表达与肿瘤预后显著相关。此外,KCTD5 的表达与免疫微环境、肿瘤相关成纤维细胞浸润和免疫相关基因的表达有关。功能富集分析表明,KCTD5 与细胞凋亡、坏死性凋亡等程序性细胞死亡有关。体外实验表明,敲低 KCTD5 促进了 A549 细胞的凋亡。相关性分析证实,KCTD5 与抗凋亡基因 Bcl-xL 和 Mcl-1 的表达呈正相关。此外,KCTD5 与多种抗肿瘤药物的敏感性显著相关。
我们的研究结果表明,KCTD5 是一种潜在的分子标志物,可用于预测泛癌患者的预后、免疫反应和药物敏感性。KCTD5 在调节程序性细胞死亡,特别是细胞凋亡中起着重要作用。